melatonin has been researched along with Fibromyalgia in 26 studies
Fibromyalgia: A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Melatonin can improve sleep quality, pain and pain threshold." | 9.19 | Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. ( Caumo, W; de Souza, IC; de Zanette, SA; Deitos, A; Laste, G; Machado, CB; Rozisky, JR; Schwertner, A; Torres, IL; Vercelino, R; Xavier, F, 2014) |
| "The aim of the study was to determine the possible effect of melatonin treatment on disturbed sleep, fatigue and pain symptoms observed in fibromyalgia (FM) patients." | 9.09 | The effect of melatonin in patients with fibromyalgia: a pilot study. ( Arias, MA; Brusco, LI; Cardinalli, DP; Citera, G; Lázaro, MA; Maldonado-Cocco, JA; Rosemffet, MG; Scheines, EJ, 2000) |
| "Melatonin improved mood, anxiety levels, and quality of life while decreasing cortisol levels in patients with fibromyalgia." | 7.91 | Melatonin Improves Mood Status and Quality of Life and Decreases Cortisol Levels in Fibromyalgia. ( Castaño, MY; Garrido, M; Gómez, MÁ; Rodríguez, AB, 2019) |
| "To assess urine levels of melatonin measured by 6-sulphatoxymelatonin (aMT6s) in patients with fibromyalgia (FM)." | 7.70 | Normal melatonin levels in patients with fibromyalgia syndrome. ( Abu-Shakra, M; Barak, R; Buskila, D; Neumann, L; Phillip, M; Press, J; Segev, Y, 1998) |
| "Fibromyalgia is a chronic syndrome characterized by widespread musculoskeletal pain and an extensive array of other symptoms including disordered sleep, fatigue, depression and anxiety." | 5.46 | Oral Supplementation of Melatonin Protects against Fibromyalgia-Related Skeletal Muscle Alterations in Reserpine-Induced Myalgia Rats. ( Bonomini, F; Favero, G; Lavazza, A; Rezzani, R; Rodella, LF; Stacchiotti, A; Trapletti, V, 2017) |
| "A systematic search of PubMed, Embase, and Scielo databases was performed, looking for articles on Melatonin and rheumatic diseases published between 1966 and August 2022." | 5.41 | Melatonin supplementation improves rheumatological disease activity: A systematic review. ( de Carvalho, JF; Skare, TL, 2023) |
| "Melatonin levels were measured by enzyme-linked immunosorbent assay." | 5.39 | Melatonin levels in premenopausal women with fibromyalgia syndrome. ( Baygutalp, F; Baykal, T; Erdal, A; Senel, K; Ugur, M, 2013) |
| "Fibromyalgia (FM) and chronic fatigue syndrome (CFS) are stress associated disorders mainly affecting women." | 5.30 | Melatonin levels in women with fibromyalgia and chronic fatigue syndrome. ( Brucksch, C; Crofford, L; Demitrack, MA; Engelberg, NC; Haus, E; Korszun, A; Masterson, L; Papadopoulos, E; Sackett-Lundeen, L, 1999) |
| " Melatonin can improve sleep quality, pain and pain threshold." | 5.19 | Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. ( Caumo, W; de Souza, IC; de Zanette, SA; Deitos, A; Laste, G; Machado, CB; Rozisky, JR; Schwertner, A; Torres, IL; Vercelino, R; Xavier, F, 2014) |
| "The aim of the study was to determine the possible effect of melatonin treatment on disturbed sleep, fatigue and pain symptoms observed in fibromyalgia (FM) patients." | 5.09 | The effect of melatonin in patients with fibromyalgia: a pilot study. ( Arias, MA; Brusco, LI; Cardinalli, DP; Citera, G; Lázaro, MA; Maldonado-Cocco, JA; Rosemffet, MG; Scheines, EJ, 2000) |
| "Melatonin improved mood, anxiety levels, and quality of life while decreasing cortisol levels in patients with fibromyalgia." | 3.91 | Melatonin Improves Mood Status and Quality of Life and Decreases Cortisol Levels in Fibromyalgia. ( Castaño, MY; Garrido, M; Gómez, MÁ; Rodríguez, AB, 2019) |
| "To assess urinary 6-sulphatoxymelatonin levels in a large consecutive series of patients with migraine and several comorbidities (chronic fatigue, fibromyalgia, insomnia, anxiety, and depression) as compared with controls." | 3.76 | Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities. ( Cipolla-Neto, J; de Souza Vieira, DS; Lin, J; Masruha, MR; Minett, TS; Peres, MF; Vilanova, LC; Zukerman, E, 2010) |
| "To assess urine levels of melatonin measured by 6-sulphatoxymelatonin (aMT6s) in patients with fibromyalgia (FM)." | 3.70 | Normal melatonin levels in patients with fibromyalgia syndrome. ( Abu-Shakra, M; Barak, R; Buskila, D; Neumann, L; Phillip, M; Press, J; Segev, Y, 1998) |
| "Fibromyalgia is a chronic widespread pain condition affecting millions of people worldwide." | 2.58 | Combination pharmacotherapy for the treatment of fibromyalgia in adults. ( Gilron, I; Moore, RA; Shum, B; Thorpe, J; Wiffen, PJ, 2018) |
| "Fibromyalgia is a clinically well-defined chronic condition with a biopsychosocial aetiology." | 2.52 | Selective serotonin reuptake inhibitors for fibromyalgia syndrome. ( Cantrell, SE; Häuser, W; Nishishinya, MB; Urrútia, G; Walitt, B, 2015) |
| "Pain is a multidimensional response involving several levels of expression ranging from somatosensory to emotional." | 2.50 | Restless legs syndrome and pain disorders: what's in common? ( Delgado Rodrigues, RN; Goulart, LI; Prieto Peres, MF, 2014) |
| "Melatonin is an endogenous indoleamine, produced mainly by the pineal gland." | 2.47 | Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies. ( Amirian, I; Gögenur, I; Reiter, RJ; Rosenberg, J; Wilhelmsen, M, 2011) |
| "Fibromyalgia has gender, age and probably hormonal associations." | 2.43 | Menopause related sleep disorders. ( Eichling, PS; Sahni, J, 2005) |
| "Fibromyalgia is a chronic syndrome characterized by widespread musculoskeletal pain and an extensive array of other symptoms including disordered sleep, fatigue, depression and anxiety." | 1.46 | Oral Supplementation of Melatonin Protects against Fibromyalgia-Related Skeletal Muscle Alterations in Reserpine-Induced Myalgia Rats. ( Bonomini, F; Favero, G; Lavazza, A; Rezzani, R; Rodella, LF; Stacchiotti, A; Trapletti, V, 2017) |
| "Melatonin levels were measured by enzyme-linked immunosorbent assay." | 1.39 | Melatonin levels in premenopausal women with fibromyalgia syndrome. ( Baygutalp, F; Baykal, T; Erdal, A; Senel, K; Ugur, M, 2013) |
| "Fibromyalgia (FM) and chronic fatigue syndrome (CFS) are stress associated disorders mainly affecting women." | 1.30 | Melatonin levels in women with fibromyalgia and chronic fatigue syndrome. ( Brucksch, C; Crofford, L; Demitrack, MA; Engelberg, NC; Haus, E; Korszun, A; Masterson, L; Papadopoulos, E; Sackett-Lundeen, L, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (15.38) | 18.2507 |
| 2000's | 8 (30.77) | 29.6817 |
| 2010's | 12 (46.15) | 24.3611 |
| 2020's | 2 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| de Carvalho, JF | 1 |
| Skare, TL | 1 |
| Hemati, K | 1 |
| Amini Kadijani, A | 1 |
| Sayehmiri, F | 1 |
| Mehrzadi, S | 1 |
| Zabihiyeganeh, M | 1 |
| Hosseinzadeh, A | 1 |
| Mirzaei, A | 1 |
| Favero, G | 2 |
| Trapletti, V | 1 |
| Bonomini, F | 2 |
| Stacchiotti, A | 1 |
| Lavazza, A | 1 |
| Rodella, LF | 1 |
| Rezzani, R | 2 |
| Thorpe, J | 1 |
| Shum, B | 1 |
| Moore, RA | 1 |
| Wiffen, PJ | 1 |
| Gilron, I | 1 |
| Castaño, MY | 1 |
| Garrido, M | 1 |
| Rodríguez, AB | 1 |
| Gómez, MÁ | 1 |
| Franco, C | 1 |
| de Zanette, SA | 1 |
| Vercelino, R | 1 |
| Laste, G | 1 |
| Rozisky, JR | 1 |
| Schwertner, A | 1 |
| Machado, CB | 1 |
| Xavier, F | 1 |
| de Souza, IC | 1 |
| Deitos, A | 1 |
| Torres, IL | 1 |
| Caumo, W | 1 |
| Goulart, LI | 1 |
| Delgado Rodrigues, RN | 1 |
| Prieto Peres, MF | 1 |
| Walitt, B | 1 |
| Urrútia, G | 1 |
| Nishishinya, MB | 1 |
| Cantrell, SE | 1 |
| Häuser, W | 1 |
| Masruha, MR | 1 |
| Lin, J | 1 |
| de Souza Vieira, DS | 1 |
| Minett, TS | 1 |
| Cipolla-Neto, J | 1 |
| Zukerman, E | 1 |
| Vilanova, LC | 1 |
| Peres, MF | 1 |
| Hussain, SA | 1 |
| Al-Khalifa, II | 1 |
| Jasim, NA | 1 |
| Gorial, FI | 1 |
| Wilhelmsen, M | 1 |
| Amirian, I | 1 |
| Reiter, RJ | 3 |
| Rosenberg, J | 1 |
| Gögenur, I | 1 |
| Mahdi, AA | 1 |
| Fatima, G | 1 |
| Das, SK | 1 |
| Verma, NS | 1 |
| Senel, K | 1 |
| Baygutalp, F | 1 |
| Baykal, T | 1 |
| Erdal, A | 1 |
| Ugur, M | 1 |
| Acuna-Castroviejo, D | 2 |
| Escames, G | 1 |
| Eichling, PS | 1 |
| Sahni, J | 1 |
| Tan, DX | 1 |
| Press, J | 1 |
| Phillip, M | 1 |
| Neumann, L | 1 |
| Barak, R | 1 |
| Segev, Y | 1 |
| Abu-Shakra, M | 1 |
| Buskila, D | 1 |
| Webb, SM | 1 |
| Wikner, J | 1 |
| Hirsch, U | 1 |
| Wetterberg, L | 1 |
| Röjdmark, S | 1 |
| Korszun, A | 1 |
| Sackett-Lundeen, L | 1 |
| Papadopoulos, E | 1 |
| Brucksch, C | 1 |
| Masterson, L | 1 |
| Engelberg, NC | 1 |
| Haus, E | 1 |
| Demitrack, MA | 1 |
| Crofford, L | 1 |
| Citera, G | 1 |
| Arias, MA | 1 |
| Maldonado-Cocco, JA | 1 |
| Lázaro, MA | 1 |
| Rosemffet, MG | 1 |
| Brusco, LI | 1 |
| Scheines, EJ | 1 |
| Cardinalli, DP | 1 |
| Klerman, EB | 1 |
| Goldenberg, DL | 1 |
| Brown, EN | 1 |
| Maliszewski, AM | 1 |
| Adler, GK | 1 |
| Dauvilliers, Y | 1 |
| Touchon, J | 1 |
| Durlach, J | 1 |
| Pagès, N | 1 |
| Bac, P | 1 |
| Bara, M | 1 |
| Guiet-Bara, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Role of Immune-pineal Axis in Fibromyalgia: Noradrenergic Modulation and Chronotherapeutic Aspects[NCT02041455] | Phase 2/Phase 3 | 66 participants (Anticipated) | Interventional | 2010-06-30 | Recruiting | ||
| "Melatonin for Migraine Prevention in Adolescents: A Pilot Remote Trial: The BRAiN-M Study"[NCT02344316] | Phase 2 | 31 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| Melatonin for Adolescent Migraine Prevention Study (The MAP Study).[NCT03150797] | Phase 2 | 72 participants (Actual) | Interventional | 2017-08-02 | Terminated (stopped due to Insufficient Fund) | ||
| Effects of Perioperative Melatonin on Sleep, Pain, and Confusion After Joint Replacement Surgery[NCT01505465] | 50 participants (Actual) | Interventional | 2012-02-29 | Completed | |||
| Benefice Assessment of Repetitive Transcranial Magnetic Stimulation Used as an Additional Procedure to Rehabilitation Exercises in Patients Suffering From Fibromyalgia[NCT01308801] | 42 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| Evaluation of Spa Therapy in the Treatment of Fibromyalgia : a Randomized, Controlled, Open Multicenter Study[NCT02265029] | 220 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants that had ≥85% headache diary compliance during weeks 12-16 of the study. (NCT02344316)
Timeframe: Weeks 12-16 of the study
| Intervention | Participants (Count of Participants) |
|---|---|
| Melatonin | 11 |
| Placebo | 10 |
eCAP tack caps will be used to measure medication adherence and the number of openings will be recorded per participant. (NCT02344316)
Timeframe: "during the At Home Active Study Period or Weeks 5-16"
| Intervention | Mean Number of Openings (Mean) |
|---|---|
| Melatonin | 39 |
| Placebo | 60 |
Number of Migraine/Migrainous Days Per 28 Day Period in melatonin group and placebo group as measured using an online/mobile device headache diary. (NCT02344316)
Timeframe: final 4 weeks of treatment
| Intervention | days (Mean) |
|---|---|
| Melatonin | 3.6 |
| Placebo | 4.9 |
Number of minutes to sleep onset as measured by a FitBit. (NCT02344316)
Timeframe: 16 weeks
| Intervention | minutes (Mean) |
|---|---|
| Melatonin | 15.2 |
| Placebo | 17.2 |
Change in mean migraine/migrainous days from weeks 5-8 of single-blind treatment phase to weeks 5-8 of randomized treatment phase for each group. (Medians reported when data were not normally distributed). (NCT03150797)
Timeframe: Weeks 5-8 of single-blind treatment phase to weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | -1 |
| Placebo Oral Capsule | 0 |
Mean CASQ score in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons. The CASQ is a 16-question instrument that uses Likert-like responses and has a score range from 16-80; higher scores indicate greater sleepiness (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | points (Mean) |
|---|---|
| Melatonin 3mg | 33 |
| Melatonin 6mg | 36 |
| Placebo Oral Capsule | 28 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 3 mg vs. placebo. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 6 mg vs. melatonin 3 mg. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 6 mg vs. placebo. (Medians reported when data were not normally distributed). (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin treated participants vs. placebo. (Ultimately, as the data were not normally distributed, medians were more appropriate). (NCT03150797)
Timeframe: weeks 5-8 of randomized treatment phase
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Number of days acute medication is used in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons. This refers to the number of days that medication for the acute treatment of headache was used during the time frame. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 5 |
| Melatonin 6mg | 3 |
| Placebo Oral Capsule | 3 |
Number of headache days in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons. This refers to number of headache days during the time period--regardless of whether they were migraine or not. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 8 |
| Melatonin 6mg | 4 |
| Placebo Oral Capsule | 5 |
Sleep time change from 96 hours before surgery to 72 hours after surgery (NCT01505465)
Timeframe: 96 hours before surgery to 72 hours after surgery
| Intervention | minutes (Mean) |
|---|---|
| Study: Melatonin | 20 |
| Control: Placebo | -55 |
11 reviews available for melatonin and Fibromyalgia
| Article | Year |
|---|---|
Melatonin supplementation improves rheumatological disease activity: A systematic review.
Topics: Arthritis, Rheumatoid; Dietary Supplements; Fibromyalgia; Humans; Melatonin; Osteoarthritis; Osteopo | 2023 |
Melatonin in the treatment of fibromyalgia symptoms: A systematic review.
Topics: Fatigue; Fibromyalgia; Humans; Melatonin; Pain; Randomized Controlled Trials as Topic | 2020 |
Combination pharmacotherapy for the treatment of fibromyalgia in adults.
Topics: 5-Hydroxytryptophan; Acetaminophen; Adult; Amitriptyline; Anti-Inflammatory Agents, Non-Steroidal; A | 2018 |
Restless legs syndrome and pain disorders: what's in common?
Topics: Calcium Channel Blockers; Diagnosis, Differential; Dopamine Agonists; Fibromyalgia; gamma-Aminobutyr | 2014 |
Selective serotonin reuptake inhibitors for fibromyalgia syndrome.
Topics: Amitriptyline; Citalopram; Fibromyalgia; Fluoxetine; Humans; Melatonin; Musculoskeletal Pain; Paroxe | 2015 |
Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies.
Topics: Analgesics; Animals; Disease Models, Animal; Fibromyalgia; Humans; Irritable Bowel Syndrome; Male; M | 2011 |
Abnormality of circadian rhythm of serum melatonin and other biochemical parameters in fibromyalgia syndrome.
Topics: Circadian Rhythm; Fibromyalgia; Humans; Melatonin; Syndrome | 2011 |
Menopause related sleep disorders.
Topics: Depression; Estrogen Replacement Therapy; Estrogens; Female; Fibromyalgia; Humans; Hydrocortisone; M | 2005 |
Melatonin therapy in fibromyalgia.
Topics: Female; Fibromyalgia; Humans; Male; Melatonin | 2007 |
[Sleep in fibromyalgia: review of clinical and polysomnographic data].
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety; Arousal; Circadian Rhythm; Depression; Female; Fib | 2001 |
[Sleep in fibromyalgia: review of clinical and polysomnographic data].
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety; Arousal; Circadian Rhythm; Depression; Female; Fib | 2001 |
[Sleep in fibromyalgia: review of clinical and polysomnographic data].
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety; Arousal; Circadian Rhythm; Depression; Female; Fib | 2001 |
[Sleep in fibromyalgia: review of clinical and polysomnographic data].
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety; Arousal; Circadian Rhythm; Depression; Female; Fib | 2001 |
Biorhythms and possible central regulation of magnesium status, phototherapy, darkness therapy and chronopathological forms of magnesium depletion.
Topics: Biological Clocks; Fatigue; Fibromyalgia; Humans; Light; Magnesium; Magnesium Deficiency; Melatonin; | 2002 |
3 trials available for melatonin and Fibromyalgia
| Article | Year |
|---|---|
Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial.
Topics: Adolescent; Adult; Amitriptyline; Analgesics; Brain-Derived Neurotrophic Factor; Double-Blind Method | 2014 |
Adjuvant use of melatonin for treatment of fibromyalgia.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Fibromyalgia; Fluox | 2011 |
The effect of melatonin in patients with fibromyalgia: a pilot study.
Topics: Administration, Oral; Adult; Aged; Anticonvulsants; Fatigue Syndrome, Chronic; Female; Fibromyalgia; | 2000 |
12 other studies available for melatonin and Fibromyalgia
| Article | Year |
|---|---|
Oral Supplementation of Melatonin Protects against Fibromyalgia-Related Skeletal Muscle Alterations in Reserpine-Induced Myalgia Rats.
Topics: Administration, Oral; Analysis of Variance; Animals; Antioxidants; Body Weight; Disease Models, Anim | 2017 |
Melatonin Improves Mood Status and Quality of Life and Decreases Cortisol Levels in Fibromyalgia.
Topics: Adult; Analgesics; Female; Fibromyalgia; Humans; Hydrocortisone; Male; Melatonin; Middle Aged; Mood | 2019 |
Mitochondrial Dysfunction in Skeletal Muscle of a Fibromyalgia Model: The Potential Benefits of Melatonin.
Topics: Animals; Biomarkers; Fibromyalgia; Locomotion; Male; Melatonin; Mitochondria; Models, Biological; Mu | 2019 |
Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Biomarkers; Comorbidity; Depressive Disorder; Down-Regul | 2010 |
Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Biomarkers; Comorbidity; Depressive Disorder; Down-Regul | 2010 |
Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Biomarkers; Comorbidity; Depressive Disorder; Down-Regul | 2010 |
Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Biomarkers; Comorbidity; Depressive Disorder; Down-Regul | 2010 |
Melatonin levels in premenopausal women with fibromyalgia syndrome.
Topics: Adult; Female; Fibromyalgia; Humans; Melatonin; Premenopause | 2013 |
Which alternative treatments work?
Topics: Back Pain; Chiropractic; Chondroitin; Cimicifuga; Complementary Therapies; Dietary Supplements; Echi | 2005 |
Melatonin therapy in fibromyalgia.
Topics: Adult; Female; Fibromyalgia; Humans; Male; Melatonin; Middle Aged | 2006 |
Normal melatonin levels in patients with fibromyalgia syndrome.
Topics: Adult; Female; Fibromyalgia; Humans; Melatonin; Middle Aged; Pain Measurement; Quality of Life; Refe | 1998 |
Fibromyalgia and melatonin: are they related?
Topics: Circadian Rhythm; Fibromyalgia; Humans; Insulin-Like Growth Factor I; Melatonin; Pineal Gland; Seaso | 1998 |
Fibromyalgia--a syndrome associated with decreased nocturnal melatonin secretion.
Topics: Adult; Biomarkers; Case-Control Studies; Circadian Rhythm; Female; Fibromyalgia; Humans; Melatonin; | 1998 |
Melatonin levels in women with fibromyalgia and chronic fatigue syndrome.
Topics: Adolescent; Adult; Circadian Rhythm; Fatigue Syndrome, Chronic; Female; Fibromyalgia; Humans; Hydroc | 1999 |
Circadian rhythms of women with fibromyalgia.
Topics: Adult; Body Temperature; Circadian Rhythm; Female; Fibromyalgia; Food; Humans; Hydrocortisone; Light | 2001 |